Prodrugs View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1985-05

AUTHORS

V. J. Stella, W. N. A. Charman, V. H. Naringrekar

ABSTRACT

Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules. More... »

PAGES

455-473

References to SciGraph publications

  • 1975. Drug Latentiation in CONCEPTS IN BIOCHEMICAL PHARMACOLOGY
  • 1972. Drug Action: Target Tissue, Dose-Response Relationships, and Receptors in PHARMACOLOGY AND PHARMACOKINETICS
  • 1977-02. Targeting of drugs in NATURE
  • 1979-10. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1958-08. Chemical Aspects of Selective Toxicity in NATURE
  • 1976-05. Ampicillin: Comparison of bioavailability and pharmacokinetics after oral and intravenous administration of three brands in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1976. Clinical Pharmacological Studies with Bacampicillin in PENICILLINS AND CEPHALOSPORINS
  • 1962. Drug Latentiation in FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG / PROGRESS IN DRUG RESEARCH / PROGRÈS DES RECHERCHES PHARMACEUTIQUES
  • 1981-09. Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Journal

    TITLE

    Drugs

    ISSUE

    5

    VOLUME

    29

    Related Patents

  • Methods And Compositions For Increasing Neurogenesis And Angiogenesis
  • Composition And Method For Muscle Repair And Regeneration
  • Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • Composition And Method For Muscle Repair And Regeneration
  • Targeted Drug Delivery Via Mixed Phosphate Derivatives
  • Calmodulin Inhibitors For The Treatment Of Ribosomal Disorders And Ribosomapathies
  • Calcium Channel Blockers For The Treatment Of Ribosomal Disorders And Ribosomapathies
  • Triptolide Lactone Ring Derivatives As Immunomodulators And Anticancer Agents
  • Phosphate Prodrugs; Treating Hiv Infection; 1-(Phosphomethyl)-3-(2-(4-Benzoylpiperazin-1-Yl)-1,2-Dioxoethyl)-4,7-Dimethoxy-1h-Pyrrolo(2,3-C)Pyridine For Example; Improved Water Solubility, Bioavailability For Oral Administration
  • Aminoquinoline Derivatives And Uses Thereof
  • Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity
  • Compositions And Methods For Treating Fibrosis
  • Random Amorphous Terpolymer Containing Lactide And Glycolide
  • Salts Of Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • Delta-2 Opioid Receptor Agonists; Protecting Cardiac And Cerebral Organs
  • Use Of Anti-Histaminics For Acute Reduction Of Elevated Intracranial Pressure
  • Substituted Pyrazinone Derivatives For Use In Mch-1 Mediated Diseases
  • Polymers Comprising Amorphous Terpolymers And Semicrystalline Blocks
  • Inhibitors Of Phosphodiesterases 11 (Pde11) And Methods Of Use To Elevate Cortisol Production
  • Bicyclo (3.1.0) Hexane-2, 6-Dicarboxylic Acid Derivatives As Mglu2 Receptor Agonist
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • Biodegradable Polymeric Materials Providing Controlled Release Of Hydrophobic Drugs From Implantable Devices
  • Methods And Compositions For Increasing Neurogenesis And Angiogenesis
  • Shear Controlled Release For Stenotic Lesions And Thrombolytic Therapies
  • Drug Combinations With Fluoro-Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
  • Coating Comprising A Terpolymer Comprising Caprolactone And Glycolide
  • Improved Raf Inhibitors
  • Treatment Of Sexual Dysfunction
  • Antibody-Enzyme Conjugates In Combination With Prodrugs For The Delivery Of Cytotoxic Agents To Tumor Cells
  • Directed Delivery Of Agents To Neural Anatomy
  • Coating Comprising A Terpolymer Comprising Caprolactone And Glycolide
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • 4-{4-[({3-Tert-Butyl-1-[3-(Hydroxymethyl) Phenyl]-1h-Pyrazol-5-Yl } Carbamoyl)-Amino] -3-Fluorophenoxy} -N-Methylpyridine-2-Carboxamide As Well As Prodrugs And Salts Thereof For The Treatment Of Cancer
  • Substituted Amino Isoxazoline Derivatives And Their Use As Anti-Depressants
  • Triptolide Derivatives For Modulation Of Apoptosis And Immunosuppression
  • Identification And Screening Of Triptolide Target Molecules
  • Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  • Aminoquinoline Derivatives And Uses Thereof
  • Inhibitors Of Late Sv40 Factor (Lsf) As Cancer Chemotherapeutics
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Terpolymers Containing Lactide And Glycolide
  • New Drug For Inhibiting Aggregation Of Proteins Involved In Diseases Linked To Protein Aggregation And/Or Neurodegenerative Diseases
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • An Absorbable Coating For Implantable Device
  • Useful As Immunosuppressive, Anti-Inflammatory And Anticancer Agents; Prepared By Reaction Of A Starting Triptolide Compound With Selenium Dioxide.
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • An Absorbable Coating For Implantable Device
  • Salts Of Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
  • Synergistic Combination Or Single Ingredient Hiv And Aids Treatments
  • Methods And Compositions For Rejuvenating Skeletal Muscle Stem Cells
  • Conjugate-Based Antifungal And Antibacterial Prodrugs
  • An Absorbable Coating For Implantable Device
  • Methods For Treating Resistant Or Refractory Tumors
  • Water Soluble Antibiotics
  • Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
  • Growth Differentiation Factor (Gdf) For Treatment Of Diastolic Heart Failure
  • Pro-Drugs For Cck Antagonists
  • Drug Combinations With Substituted Diaryl Ureas For The Treatment Of Cancer
  • Inhibitors Of Fructose 1,6-Bisphosphatase And Methods Of Use Thereof
  • Dihydropteridinones As Plk Inhibitors
  • Substituted Carbonate And Carbamate Derivatives Of Triptolide Compounds As Anticarcinogenic And Antiinflammatory Agents
  • 4-{4- [ ({3-Tert-Butyl-1- [3- (Hydroxymethyl) Phenyl] - 1h- Pyrazol- 5 -Yl } Carbamoyl) -Amin O] -3-Chlorophenoxy} -N-Methylpyridine-2-Carboxamide As An Inhibitor Of The Vegfr Kinase For The Treatment Of Cancer
  • Targeted Drug Delivery Via Mixed Phosphate Derivatives
  • Methods For Isolation Of Triptolide Compounds From Tripterygium Wilfordii
  • Tri-Block Copolymer Comprising Two Polyester Blocks And A Poly(Ethylene Glycol) Block
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002

    DOI

    http://dx.doi.org/10.2165/00003495-198529050-00002

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1022482439

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3891303


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Absorption", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenal Cortex Hormones", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood-Brain Barrier", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chloramphenicol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Stability", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug-Related Side Effects and Adverse Reactions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pain", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pharmaceutical Preparations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phenytoin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Solubility", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulindac", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Taste", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stella", 
            "givenName": "V. J.", 
            "id": "sg:person.010653152735.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010653152735.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Charman", 
            "givenName": "W. N. A.", 
            "id": "sg:person.01166642247.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166642247.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA", 
              "id": "http://www.grid.ac/institutes/grid.266515.3", 
              "name": [
                "Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Naringrekar", 
            "givenName": "V. H.", 
            "id": "sg:person.016474031570.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016474031570.97"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/182421a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028596561", 
              "https://doi.org/10.1038/182421a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-46314-3_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051654474", 
              "https://doi.org/10.1007/978-3-642-46314-3_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4684-3126-1_19", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038094483", 
              "https://doi.org/10.1007/978-1-4684-3126-1_19"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00558335", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026583165", 
              "https://doi.org/10.1007/bf00558335"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/265407a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016845186", 
              "https://doi.org/10.1038/265407a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1981.174", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028323260", 
              "https://doi.org/10.1038/clpt.1981.174"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4684-2055-5_9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027313220", 
              "https://doi.org/10.1007/978-1-4684-2055-5_9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-0348-7044-3_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039902569", 
              "https://doi.org/10.1007/978-3-0348-7044-3_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01062386", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028952932", 
              "https://doi.org/10.1007/bf01062386"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1985-05", 
        "datePublishedReg": "1985-05-01", 
        "description": "Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003495-198529050-00002", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1084788", 
            "issn": [
              "0012-6667", 
              "1179-1950"
            ], 
            "name": "Drugs", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "29"
          }
        ], 
        "keywords": [
          "drug molecules", 
          "parent drug molecule", 
          "chemical experience", 
          "chemical derivatives", 
          "prodrug approach", 
          "molecules", 
          "prodrug", 
          "clinical efficacy", 
          "clinical usefulness", 
          "active drug", 
          "scientific rationale", 
          "derivatives", 
          "drugs", 
          "efficacy", 
          "review", 
          "transformation", 
          "rationale", 
          "usefulness", 
          "experience", 
          "body", 
          "means", 
          "order", 
          "example", 
          "different ways", 
          "design", 
          "approach", 
          "way", 
          "problem"
        ], 
        "name": "Prodrugs", 
        "pagination": "455-473", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1022482439"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003495-198529050-00002"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3891303"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003495-198529050-00002", 
          "https://app.dimensions.ai/details/publication/pub.1022482439"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:46", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_203.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003495-198529050-00002"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-198529050-00002'


     

    This table displays all metadata directly associated to this object as RDF triples.

    195 TRIPLES      21 PREDICATES      77 URIs      60 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003495-198529050-00002 schema:about N3998534f27b9455295de0151b303c657
    2 N47708ef45fbd40b79287221123205958
    3 N63f122cfb3bd407e999f27f8bf567ede
    4 N65929601461741a49bfcb9d728e0d064
    5 N7bc6bf61822249c8a2d857ecc8cc07ea
    6 N7d4faf968e174cf793a0d6789b952bf3
    7 Na34166bc0fc34f77885eb16a63f3bf8d
    8 Nacf12e6afe4848b0b1cce8376dd15eb5
    9 Nbcf81baf3aa8413d8136532c87be5cb4
    10 Nbe9742d2fd164c06bfe859e6fee84309
    11 Nc8369b1d17294be7882589ba5089af50
    12 Ncb89fedcc18b443793caf1e68e97e7eb
    13 Nf0fc7cb435cc4eaea86d2a4b49e72731
    14 Nf25a5ddbcc8e4687bea678fb36d562d4
    15 anzsrc-for:11
    16 anzsrc-for:1115
    17 schema:author N23dfc0afd99e485eaed83d5b7edcee04
    18 schema:citation sg:pub.10.1007/978-1-4684-2055-5_9
    19 sg:pub.10.1007/978-1-4684-3126-1_19
    20 sg:pub.10.1007/978-3-0348-7044-3_2
    21 sg:pub.10.1007/978-3-642-46314-3_3
    22 sg:pub.10.1007/bf00558335
    23 sg:pub.10.1007/bf01062386
    24 sg:pub.10.1038/182421a0
    25 sg:pub.10.1038/265407a0
    26 sg:pub.10.1038/clpt.1981.174
    27 schema:datePublished 1985-05
    28 schema:datePublishedReg 1985-05-01
    29 schema:description Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.
    30 schema:genre article
    31 schema:isAccessibleForFree false
    32 schema:isPartOf N4ca45a1013a34de6a56020f61d87d2cc
    33 Ndf5d781eef4b4ad58fb4159ad1b44eb0
    34 sg:journal.1084788
    35 schema:keywords active drug
    36 approach
    37 body
    38 chemical derivatives
    39 chemical experience
    40 clinical efficacy
    41 clinical usefulness
    42 derivatives
    43 design
    44 different ways
    45 drug molecules
    46 drugs
    47 efficacy
    48 example
    49 experience
    50 means
    51 molecules
    52 order
    53 parent drug molecule
    54 problem
    55 prodrug
    56 prodrug approach
    57 rationale
    58 review
    59 scientific rationale
    60 transformation
    61 usefulness
    62 way
    63 schema:name Prodrugs
    64 schema:pagination 455-473
    65 schema:productId N0cb1a5834cc44e37bd1d792ebf45f960
    66 N854869c0441d4b9da400173fcff72987
    67 Na7d863aa83f94bf49664f22af7242023
    68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022482439
    69 https://doi.org/10.2165/00003495-198529050-00002
    70 schema:sdDatePublished 2022-09-02T15:46
    71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    72 schema:sdPublisher Ne6d31d9d6e394bff8388e4f897b3f3db
    73 schema:url https://doi.org/10.2165/00003495-198529050-00002
    74 sgo:license sg:explorer/license/
    75 sgo:sdDataset articles
    76 rdf:type schema:ScholarlyArticle
    77 N0cb1a5834cc44e37bd1d792ebf45f960 schema:name dimensions_id
    78 schema:value pub.1022482439
    79 rdf:type schema:PropertyValue
    80 N19bb55be7fd04711870f396a1d91712c rdf:first sg:person.01166642247.11
    81 rdf:rest Nac154f5619894082873160925193513f
    82 N23dfc0afd99e485eaed83d5b7edcee04 rdf:first sg:person.010653152735.32
    83 rdf:rest N19bb55be7fd04711870f396a1d91712c
    84 N3998534f27b9455295de0151b303c657 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Drug Therapy
    86 rdf:type schema:DefinedTerm
    87 N47708ef45fbd40b79287221123205958 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Humans
    89 rdf:type schema:DefinedTerm
    90 N4ca45a1013a34de6a56020f61d87d2cc schema:volumeNumber 29
    91 rdf:type schema:PublicationVolume
    92 N63f122cfb3bd407e999f27f8bf567ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Drug Stability
    94 rdf:type schema:DefinedTerm
    95 N65929601461741a49bfcb9d728e0d064 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Adrenal Cortex Hormones
    97 rdf:type schema:DefinedTerm
    98 N7bc6bf61822249c8a2d857ecc8cc07ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Sulindac
    100 rdf:type schema:DefinedTerm
    101 N7d4faf968e174cf793a0d6789b952bf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Absorption
    103 rdf:type schema:DefinedTerm
    104 N854869c0441d4b9da400173fcff72987 schema:name pubmed_id
    105 schema:value 3891303
    106 rdf:type schema:PropertyValue
    107 Na34166bc0fc34f77885eb16a63f3bf8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Chloramphenicol
    109 rdf:type schema:DefinedTerm
    110 Na7d863aa83f94bf49664f22af7242023 schema:name doi
    111 schema:value 10.2165/00003495-198529050-00002
    112 rdf:type schema:PropertyValue
    113 Nac154f5619894082873160925193513f rdf:first sg:person.016474031570.97
    114 rdf:rest rdf:nil
    115 Nacf12e6afe4848b0b1cce8376dd15eb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Drug-Related Side Effects and Adverse Reactions
    117 rdf:type schema:DefinedTerm
    118 Nbcf81baf3aa8413d8136532c87be5cb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Taste
    120 rdf:type schema:DefinedTerm
    121 Nbe9742d2fd164c06bfe859e6fee84309 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Pharmaceutical Preparations
    123 rdf:type schema:DefinedTerm
    124 Nc8369b1d17294be7882589ba5089af50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Solubility
    126 rdf:type schema:DefinedTerm
    127 Ncb89fedcc18b443793caf1e68e97e7eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Blood-Brain Barrier
    129 rdf:type schema:DefinedTerm
    130 Ndf5d781eef4b4ad58fb4159ad1b44eb0 schema:issueNumber 5
    131 rdf:type schema:PublicationIssue
    132 Ne6d31d9d6e394bff8388e4f897b3f3db schema:name Springer Nature - SN SciGraph project
    133 rdf:type schema:Organization
    134 Nf0fc7cb435cc4eaea86d2a4b49e72731 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Pain
    136 rdf:type schema:DefinedTerm
    137 Nf25a5ddbcc8e4687bea678fb36d562d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Phenytoin
    139 rdf:type schema:DefinedTerm
    140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    141 schema:name Medical and Health Sciences
    142 rdf:type schema:DefinedTerm
    143 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    144 schema:name Pharmacology and Pharmaceutical Sciences
    145 rdf:type schema:DefinedTerm
    146 sg:journal.1084788 schema:issn 0012-6667
    147 1179-1950
    148 schema:name Drugs
    149 schema:publisher Springer Nature
    150 rdf:type schema:Periodical
    151 sg:person.010653152735.32 schema:affiliation grid-institutes:grid.266515.3
    152 schema:familyName Stella
    153 schema:givenName V. J.
    154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010653152735.32
    155 rdf:type schema:Person
    156 sg:person.01166642247.11 schema:affiliation grid-institutes:grid.266515.3
    157 schema:familyName Charman
    158 schema:givenName W. N. A.
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166642247.11
    160 rdf:type schema:Person
    161 sg:person.016474031570.97 schema:affiliation grid-institutes:grid.266515.3
    162 schema:familyName Naringrekar
    163 schema:givenName V. H.
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016474031570.97
    165 rdf:type schema:Person
    166 sg:pub.10.1007/978-1-4684-2055-5_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027313220
    167 https://doi.org/10.1007/978-1-4684-2055-5_9
    168 rdf:type schema:CreativeWork
    169 sg:pub.10.1007/978-1-4684-3126-1_19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038094483
    170 https://doi.org/10.1007/978-1-4684-3126-1_19
    171 rdf:type schema:CreativeWork
    172 sg:pub.10.1007/978-3-0348-7044-3_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039902569
    173 https://doi.org/10.1007/978-3-0348-7044-3_2
    174 rdf:type schema:CreativeWork
    175 sg:pub.10.1007/978-3-642-46314-3_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051654474
    176 https://doi.org/10.1007/978-3-642-46314-3_3
    177 rdf:type schema:CreativeWork
    178 sg:pub.10.1007/bf00558335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026583165
    179 https://doi.org/10.1007/bf00558335
    180 rdf:type schema:CreativeWork
    181 sg:pub.10.1007/bf01062386 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028952932
    182 https://doi.org/10.1007/bf01062386
    183 rdf:type schema:CreativeWork
    184 sg:pub.10.1038/182421a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028596561
    185 https://doi.org/10.1038/182421a0
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1038/265407a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016845186
    188 https://doi.org/10.1038/265407a0
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1038/clpt.1981.174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028323260
    191 https://doi.org/10.1038/clpt.1981.174
    192 rdf:type schema:CreativeWork
    193 grid-institutes:grid.266515.3 schema:alternateName Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA
    194 schema:name Department of Pharmaceutical Chemistry, University of Kansas, School of Pharmacy, 66045, Lawrence, KS, USA
    195 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...